These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34216767)

  • 1. Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs.
    Maturavongsadit P; Shrivastava R; Sykes C; Cottrell ML; Montgomery SA; Kashuba ADM; Rahima Benhabbour S
    Int J Pharm; 2021 Aug; 605():120844. PubMed ID: 34216767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new engineering process of biodegradable polymeric solid implants for ultra-long-acting drug delivery.
    Maturavongsadit P; Paravyan G; Kovarova M; Garcia JV; Benhabbour SR
    Int J Pharm X; 2021 Dec; 3():100068. PubMed ID: 33392498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.
    Ribera E
    AIDS Rev; 2018; 20(4):179-186. PubMed ID: 30548024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.
    Hester EK; Astle K
    Ann Pharmacother; 2019 Aug; 53(8):860-866. PubMed ID: 30758229
    [No Abstract]   [Full Text] [Related]  

  • 5. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery.
    Benhabbour SR; Kovarova M; Jones C; Copeland DJ; Shrivastava R; Swanson MD; Sykes C; Ho PT; Cottrell ML; Sridharan A; Fix SM; Thayer O; Long JM; Hazuda DJ; Dayton PA; Mumper RJ; Kashuba ADM; Victor Garcia J
    Nat Commun; 2019 Sep; 10(1):4324. PubMed ID: 31541085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
    Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
    Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
    Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
    Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy.
    Young IC; Pallerla A; Cottrell ML; Maturavongsadit P; Prasher A; Shrivastava R; De la Cruz G; Montgomery SA; Schauer A; Sykes C; Kashuba ADM; Benhabbour SR
    J Control Release; 2023 Nov; 363():606-620. PubMed ID: 37797892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging.
    Solorio L; Olear AM; Hamilton JI; Patel RB; Beiswenger AC; Wallace JE; Zhou H; Exner AA
    Theranostics; 2012; 2(11):1064-77. PubMed ID: 23227123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
    Revuelta-Herrero JL; Chamorro-de-Vega E; Rodríguez-González CG; Alonso R; Herranz-Alonso A; Sanjurjo-Sáez M
    Ann Pharmacother; 2018 Jan; 52(1):11-18. PubMed ID: 28836468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
    Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.
    Melody K; McBeth S; Kline C; Kashuba AD; Mellors JW; Ambrose Z
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7762-70. PubMed ID: 26438501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
    Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
    Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
    Taramasso L; Tatarelli P; Ricci E; Madeddu G; Menzaghi B; Squillace N; De Socio GV; Martinelli C; Gulminetti R; Maggi P; Orofino G; Vichi F; Di Biagio A; Bonfanti P;
    BMC Infect Dis; 2018 Jul; 18(1):357. PubMed ID: 30064371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Juluca for Human Immunodeficiency Virus Infection Treatment in Virologically Suppressed Adults in Taiwan.
    Anderson SJ; Hsu CY; Ou HT; Ko NY; Yang CT; Lopes S
    Value Health Reg Issues; 2021 May; 24():216-223. PubMed ID: 33857719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.
    Casado JL; Monsalvo M; Rojo AM; Fontecha M; Rodriguez-Sagrado MA
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):561-570. PubMed ID: 29775399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
    Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
    Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Acting Antiretrovirals: Where Are We now?
    Nyaku AN; Kelly SG; Taiwo BO
    Curr HIV/AIDS Rep; 2017 Apr; 14(2):63-71. PubMed ID: 28303548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir-rilpivirine coformulation.
    Sun HY; Chang SY; Hung CC
    Curr Opin HIV AIDS; 2018 Jul; 13(4):320-325. PubMed ID: 29553948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension.
    Mc Crudden MTC; Larrañeta E; Clark A; Jarrahian C; Rein-Weston A; Lachau-Durand S; Niemeijer N; Williams P; Haeck C; McCarthy HO; Zehrung D; Donnelly RF
    J Control Release; 2018 Dec; 292():119-129. PubMed ID: 30395897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.